Core Viewpoint - Jinbo Bio is leveraging its first-mover advantage and original innovation capabilities to establish a "license barrier" in the industry, aiming to become a world-class technology-driven bio-materials enterprise amidst increasing competition [2]. Group 1: Product Development and Innovation - Jinbo Bio has made significant breakthroughs with its core products, including the first international discovery and analysis of the atomic structure of type III collagen, which features a flexible helical structure at 164.88° [3]. - The company has developed the first original bio-material with independent intellectual property rights in China, including a broad-spectrum anti-HPV bio-protein and a multi-peptide drug for COVID-19 [3][4]. - Jinbo Bio holds three class III medical device registration certificates for recombinant human collagen, covering all dosage forms including freeze-dried fibers, solutions, and gels [3][7]. Group 2: Research and Development - The company has completed 12 projects on the atomic structure of human collagen, aiming to develop more innovative and differentiated products [4]. - Jinbo Bio has developed the "AI Collagen Brain System" to enhance research efficiency and reliability, collaborating with several universities and research institutions to establish research platforms [5]. Group 3: Industry Standards and Market Position - Jinbo Bio has participated in the formulation of multiple industry standards and is expanding into international standards, enhancing its influence in the global biopharmaceutical field [6]. - The company has maintained a leading position in the recombinant human collagen sector, despite increased competition, by leveraging its established clinical data and distribution networks [7]. Group 4: Strategic Development and Future Plans - Jinbo Bio is constructing a recombinant human collagen industrial park in collaboration with the Shanxi Comprehensive Reform Demonstration Zone to attract upstream and downstream enterprises [8]. - The company plans to enhance its product matrix and distribution channels, focusing on innovative product development and expanding market coverage through partnerships and brand promotion [8][9]. - Jinbo Bio aims to become an internationally leading bio-materials enterprise by deepening basic research and applying new technologies in the healthcare sector [9].

锦波生物（920982）12月9日大宗交易平台出现一笔成交，成交量2.50万股，成交金额750.00万元，大宗 交易成交价为300.00元，相对今日收盘价溢价28.58%。该笔交易的买方营业部为中信证券股份有限公司 大连高新园区证券营业部，卖方营业部为华泰证券股份有限公司南京长江路证券营业部。 进一步统计，近1个月内该股累计发生4笔大宗交易，合计成交金额为2124.00万元。 证券时报·数据宝统计显示，锦波生物今日收盘价为233.31元，上涨0.62%，日换手率为1.64%，成交额 为2.11亿元，近5日该股累计上涨4.42%。（数据宝） 12月9日锦波生物大宗交易一览 | 成交量 | 成交金额 | 成交价格 | 相对当日收 盘价折溢价 | 买方营业部 | 卖方营业部 | | --- | --- | --- | --- | --- | --- | | （万股） | （万元） | （元） | | | | | | | | （%） | | | | 2.50 | 750.00 | 300.00 | 28.58 | 中信证券股份有限公司 大连高新园区证券营业 | 华泰证券股份有限公司 南京长江路证券营业部 | | | ...

免责声明：本文内容与数据仅供参考，不构成投资建议，使用前核实。据此操作，风险自担。 每日经济新闻 （记者 曾健辉） 每经讯，2025年12月9日，北交所上市公司锦波生物（920982，收盘价：233.31元）发生一笔大宗交易，成交价300元/股，成交 数量2.5万股，成交金额750万元，溢价28.58%。买入营业部是中信证券股份有限公司大连高新园区证券营业部，卖出营业部是 华泰证券股份有限公司南京长江路证券营业部。 ...

Group 1 - The core point of the article highlights a significant block trade involving Jinbo Biological, with a transaction volume of 20,000 shares and a transaction amount of 5.98 million yuan, executed at a price of 299.00 yuan, representing a premium of 32.59% over the closing price of the day [2][3] - In the past month, Jinbo Biological has recorded a total of three block trades, amounting to a cumulative transaction value of 13.74 million yuan [3] - The closing price of Jinbo Biological on the day of the block trade was 225.51 yuan, reflecting a decrease of 2.25%, with a trading volume of 2.53 billion yuan and a turnover rate of 2.00% [3] Group 2 - Jinbo Biological was established on March 28, 2008, with a registered capital of 1.1506534 billion yuan [3] - The buyer in the recent block trade was CITIC Securities Co., Ltd., Dalian High-tech Zone Securities Business Department, while the seller was Huatai Securities Co., Ltd., Nanjing Changjiang Road Securities Business Department [2][3]

Group 1 - The core point of the news is that Jinbo Biological (920982) executed a block trade on December 3, with a transaction volume of 17,000 shares and a transaction amount of 4.93 million yuan, at a price of 290.00 yuan, which represents a premium of 25.70% over the closing price of the day [2][3] - The buyer of the block trade was CITIC Securities Co., Ltd. Dalian High-tech Park Securities Business Department, while the seller was Huatai Securities Co., Ltd. Nanjing Changjiang Road Securities Business Department [2][3] - In the past month, Jinbo Biological has recorded a total of 2 block trades, with a cumulative transaction amount of 7.76 million yuan [3] Group 2 - The closing price of Jinbo Biological on the day of the block trade was 230.71 yuan, reflecting an increase of 3.26%, with a turnover rate of 2.75% and a total transaction amount of 347 million yuan [3] - Over the past five days, the stock has increased by 6.66% [3] - Jinbo Biological was established on March 28, 2008, with a registered capital of 1,150.6534 million yuan [3]

Core Viewpoint - On December 2, 2023, a block trade of 10,000 shares of Jinbo Biological (920982) was executed at a price of 283.00 CNY, representing a premium of 26.66% over the closing price of the day [2] Summary by Relevant Sections Block Trade Details - The transaction volume was 10,000 shares with a total transaction value of 2.83 million CNY [2] - The block trade price was 283.00 CNY, which is a 26.66% premium compared to the closing price of 223.43 CNY [2] - The buyer was CITIC Securities Co., Ltd. from the Dalian High-tech Zone Securities Branch, while the seller was Huatai Securities Co., Ltd. from the Nanjing Changjiang Road Securities Branch [2] Stock Performance - On the same day, Jinbo Biological's stock closed at 223.43 CNY, marking an increase of 2.42% [2] - The stock had a turnover rate of 2.05% and a total trading volume of 253 million CNY for the day [2] - Over the past five days, the stock has accumulated a rise of 3.07% [2] Company Background - Jinbo Biological Pharmaceutical Co., Ltd. was established on March 28, 2008, with a registered capital of 1.1506534 billion CNY [2]

Market Overview - On December 2, the A-share market saw a collective decline in the three major indices, with the Shanghai Composite Index down by 0.42%, the Shenzhen Component Index down by 0.68%, and the ChiNext Index down by 0.69% [1] - The total trading volume in the Shanghai and Shenzhen markets was approximately 1,593.43 billion yuan, a decrease of about 280.51 billion yuan compared to the previous trading day [1] - Out of the total stocks, 1,544 rose while 3,740 fell, with 54 hitting the daily limit up and 7 hitting the daily limit down [1] Sector Performance - The sectors that performed well included Fujian state-owned assets, forestry, prepared dishes, coal mining, airports, and light manufacturing [1] - Conversely, sectors that saw declines included non-ferrous metals, antimony, MLCC, lithium mining, energy metals, precious metals, and bioproducts [1] Commodity Futures - In the domestic commodity futures market, there were mixed results, with BR rubber rising by approximately 4%, and silver and pulp increasing by over 2% [1] - Other commodities such as coking coal and soda ash saw increases of over 1%, while asphalt and platinum fell by more than 2% [1] Shanxi Sector Analysis - In the Shanxi sector on December 2, there were 41 stocks, with 12 rising and 27 falling, indicating a significant number of declines [2] - Among the rising stocks, Antai Group led with a peak increase of 9.96%, while Taiyuan Iron & Steel rose by 7.06% [2] - Other notable gainers included Huayang Co. with a 3.57% increase, Jinbo Biological with a 2.42% increase, and Yongtai Energy with a 1.23% increase [2] - The leading decliner was Dongjie Intelligent, which fell by 3.62%, followed by Beifang Copper, Pailin Biological, Keda Automation, and Kuaijingtong with respective declines of 2.69%, 2.32%, 2.01%, and 1.72% [2]

Group 1 - The core point of the article is that Jinbo Bio has received a Class D medical device registration certificate from the Philippine authorities for its type III humanized collagen freeze-dried fiber [2] - The product is intended for facial dermal tissue filling to correct dynamic wrinkles in the forehead area, including frown lines, forehead lines, and crow's feet [2]

从资金流向上来看，当日医疗美容板块主力资金净流出5875.57万元，游资资金净流入1690.61万元，散户 资金净流入4184.96万元。医疗美容板块个股资金流向见下表： 证券之星消息，11月24日医疗美容板块较上一交易日上涨0.27%，*ST美谷领涨。当日上证指数报收于 3836.77，上涨0.05%。深证成指报收于12585.08，上涨0.37%。医疗美容板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 000615 | *ST美谷 | 4.07 | 4.63% | 28.52万 | | 1.15亿 | | 688363 | 华熙生物 | 49.78 | 1.86% | 1.87万 | | 9268.75万 | | 300896 | 爱美客 | 66'56 | -1.36% | 2.41万 | | 3.52亿 | | 920982 | 锦波生物 | 216.59 | -1.55% | 7336.92 | | 1.60亿 | | 代码 | 名称 | 主力净流 ...

Core Viewpoint - The article highlights the rapid rise of Jinbo Biotechnology, a company founded by Yang Xia, in the biopharmaceutical industry in Shanxi, showcasing its innovative achievements in recombinant collagen products and its significant market presence after listing on the Beijing Stock Exchange [1][8]. Company Overview - Jinbo Biotechnology was established in 2008 by Yang Xia, who aimed to develop synthetic collagen to reduce the high costs and improve the success rates of organ transplants [3][4]. - The company successfully developed the world's first recombinant type III humanized collagen gel without cross-linking agents, marking a significant technological breakthrough [11][19]. Financial Performance - From 2021 to 2024, Jinbo Biotechnology's revenue increased from 233 million yuan to 1.443 billion yuan, and after its listing in July 2023, the company's market capitalization approached 30 billion yuan, making it a leading stock on the Beijing Stock Exchange [8][19]. Product Development - Jinbo's recombinant type III humanized collagen has identical amino acid sequences to natural type III collagen and is used in various applications, including advanced implant materials and skincare products [6][11]. - The company has developed a range of products, including the "Wei Yi Mei" series, which became the first injectable-grade human collagen product to be commercialized globally [6][8]. Technological Innovation - Jinbo Biotechnology emphasizes original innovation, having established a fully integrated production facility for humanized collagen products, utilizing advanced technologies such as industrial IoT and AI [11][19]. - The company has participated in setting industry standards for recombinant collagen, further solidifying its leadership position in the global market [13][19]. Strategic Partnerships - In June 2023, Jinbo Biotechnology attracted significant investment from strategic partners, including Nongfu Spring and Wantai BioPharma, indicating strong confidence in the company's growth prospects [18]. - The collaboration aims to enhance the company's capabilities and expand its market reach, particularly in the health and beauty sectors [18][19]. Future Outlook - Jinbo Biotechnology plans to continue advancing its research in recombinant collagen technology and expand its product offerings in the healthcare and life care sectors, aiming to become a leading innovative biopharmaceutical company [19][21].